{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T08:58:05Z","timestamp":1784365085970,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T00:00:00Z","timestamp":1288656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:p>Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients.\u2028Clin Transplant 2011: 25: 541\u2013548. \u00a9 2010 John Wiley &amp; Sons A\/S.<\/jats:p><jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Skin cancers are the most common malignancies in solid organ transplant recipients (SOTR). A case\u2010observational, retrospective study was performed to determine the efficacy of low\u2010dose capecitabine in the secondary prevention of skin cancers in SOTRs treated at a single institution. SOTRs with recurrent squamous cell carcinoma (SCC) and\/or basal cell carcinoma (BCC) were given low\u2010dose capecitabine 1\u2003g\/m<jats:sup>2<\/jats:sup> daily, days 1\u201314 of a 21\u2010d treatment cycle. Skin surveillance was performed by dermatologists every 1\u20133\u2003months. Cumulative incidence rates of SCC, BCC, and actinic keratosis (AK) before and after treatment were scored and statistically compared for each patient using a non\u2010parametric Wilcoxon signed rank test. Fifteen patients (13 men and two women) with a median age of 57\u2003yr (range 40\u201373) were treated. Incidence rates as measured by mean number of events per month declined by 0.33 for SCC, 0.04 for BCC, and 2.45 for AK (p\u2003&lt;\u20030.05). The most common grade 3 and 4 toxicities included fatigue (40.0%), hand\u2010foot syndrome (20.0%), and diarrhea (20.0%). The discontinuation rate at one\u2003yr was approximately 33.3%. We conclude that oral capecitabine significantly decreases the incidence rates of recurrent SCC, BCC, and AK in SOTRs and is associated with manageable toxicity.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2010.01348.x","type":"journal-article","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T18:03:17Z","timestamp":1288807397000},"page":"541-548","source":"Crossref","is-referenced-by-count":62,"title":["Capecitabine for skin cancer prevention in solid organ transplant recipients"],"prefix":"10.1111","volume":"25","author":[{"given":"Tanawat","family":"Jirakulaporn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Endrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josy","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz Z.","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50130"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.06.048"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(96)00152-2"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199603150-00008"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90239-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70185-4"},{"key":"e_1_2_6_8_2","first-page":"1172","article-title":"Non\u2010lymphoid cancer after liver transplantation","volume":"44","author":"Frezza EE","year":"1997","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-128"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205270-00008"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005090993"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(00)01487-1"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30250-8"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1747.2004.23440.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.30150.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1933"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2002.00613.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)01831-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92459-S"},{"key":"e_1_2_6_20_2","first-page":"175","volume-title":"Skin Diseases after Organ Transplantation","author":"Euvrard S","year":"1998"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.49297.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.8.985"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08269.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70122-X"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07616.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-004-0656-6"},{"key":"e_1_2_6_28_2","first-page":"134","article-title":"Safety of chronic low\u2010dose capecitabine as maintenance therapy in gastrointestinal cancers","volume":"3","author":"Sun JF","year":"2009","journal-title":"Gastrointest Cancer Res"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2010.01348.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2010.01348.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:25:46Z","timestamp":1697376346000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2010.01348.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,2]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1111\/j.1399-0012.2010.01348.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2010.01348.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,2]]}}}